ID   BON1 RR1
AC   CVCL_WV97
SY   RR1
DR   cancercelllines; CVCL_WV97
DR   Wikidata; Q93430380
RX   DOI=10.1530/endoabs.49.EP154;
RX   PubMed=29895527;
CC   Selected for resistance to: ChEBI; CHEBI:68478; Everolimus (RAD001).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1317Gln (c.3949G>C); ClinVar=VCV000000829; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Cys1960Tyr (c.5879G>A); ClinVar=VCV000038003; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C4446; Pancreatic serotonin-producing neuroendocrine tumor
DI   ORDO; Orphanet_506090; Serotonin-producing neuroendocrine tumor of pancreas
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_3985 ! BON-1
SX   Male
AG   28Y
CA   Cancer cell line
DT   Created: 06-09-19; Last updated: 10-09-24; Version: 9
//
RX   DOI=10.1530/endoabs.49.EP154;
RA   Aristizabal Prada E.T., Maurer J., Spottl G., Auernhammer C.J.,
RA   Nolting S.;
RT   "Development of an everolimus-resistant BON1 cell line with altered cell
RT   cycle and c-Met activity.";
RL   Endocr. Abstr. 49:EP154-EP154(2017).
//
RX   PubMed=29895527; DOI=10.1530/ERC-18-0159; PMCID=PMC7439002;
RA   Aristizabal Prada E.T., Spottl G., Maurer J., Lauseker M.,
RA   Koziolek E.J., Schrader J., Grossman A., Pacak K., Beuschlein F.,
RA   Auernhammer C.J., Nolting S.;
RT   "The role of GSK3 and its reversal with GSK3 antagonism in everolimus
RT   resistance.";
RL   Endocr. Relat. Cancer 25:893-908(2018).
//